|
| 37345484 | Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia. | Haematologica | 2024 |
| 37941406 | Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase. | Haematologica | 2024 |
| 36355853 | Applying CRISPR-Cas9 screens to dissect hematological malignancies. | Blood Adv | 2023 |
| 37801638 | Total Synthesis of the 2,5-Disubstituted γ-Pyrone E1 UAE Inhibitor Himeic Acid A. | Org Lett | 2023 |
| 37498585 | ZDHHC21: a mitochondrial vulnerability in AML. | Blood | 2023 |
| 36732677 | Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis. | Eur J Haematol | 2023 |
| 36794878 | Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia. | Br J Haematol | 2023 |
| 36481232 | Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis. | Trends Cell Biol | 2023 |
| 35165102 | Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer. | Clin Cancer Res | 2022 |
| 35668135 | The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. | Nat Cell Biol | 2022 |
| 35667842 | Translational Control by 4E-BP1/2 Suppressor Proteins Regulates Mitochondrial Biosynthesis and Function during CD8<sup>+</sup> T Cell Proliferation. | J Immunol | 2022 |
| 35492819 | Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations. | JACC CardioOncol | 2022 |
| 35365596 | Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. | Signal Transduct Target Ther | 2022 |
| 35385187 | Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study. | Am J Hematol | 2022 |
| 36819167 | Safety of re-challenging adults with acute lymphoblastic leukemia with PEG-asparaginase-induced severe hypertriglyceridemia when treated with a pediatric-inspired regimen. | EJHaem | 2022 |
| 36407947 | Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer. | ACS Pharmacol Transl Sci | 2022 |
| 36332954 | Traumatic stress symptoms in family caregivers of patients with acute leukaemia: protocol for a multisite mixed methods, longitudinal, observational study. | BMJ Open | 2022 |
| 36321400 | What doesn't kill you makes you stronger - <i>bcl-2</i> promotes survival independent of proliferation. | Haematologica | 2022 |
| 36084291 | Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes. | ACS Chem Biol | 2022 |
| 35185150 | Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. | Signal Transduct Target Ther | 2022 |
| 35169231 | Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. | Commun Biol | 2022 |
| 33177128 | E1 Enzymes as Therapeutic Targets in Cancer. | Pharmacol Rev | 2021 |
| 33720355 | Very long chain fatty acid metabolism is required in acute myeloid leukemia. | Blood | 2021 |
| 33767401 | Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. | Bone Marrow Transplant | 2021 |
| 33594052 | Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. | Nat Commun | 2021 |
| 33922062 | Mitochondrial ATP-Dependent Proteases-Biological Function and Potential Anti-Cancer Targets. | Cancers (Basel) | 2021 |
| 33504581 | Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia. | Cancer Discov | 2021 |
| 34616866 | Novel subtypes of <i>NPM1</i>-mutated AML with distinct outcome. | Mol Cell Oncol | 2021 |
| 34292323 | Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. | Blood | 2021 |
| 34031589 | Mammary epithelial cells have lineage-rooted metabolic identities. | Nat Metab | 2021 |
| 31896684 | Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. | Haematologica | 2021 |
| 31857370 | Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia. | Haematologica | 2021 |
| 33476303 | A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity. | JCI Insight | 2021 |
| 31001692 | Emotion And Symptom-focused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. | Support Care Cancer | 2020 |
| 33704181 | Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. | Curr Oncol | 2020 |
| 33377057 | Transduction of Primary AML Cells with Lentiviral Vector for <i>In Vitro</i> Study or <i>In Vivo</i> Engraftment. | STAR Protoc | 2020 |
| 33241109 | Mitochondria regulate AML differentiation independent of oxidative phosphorylation and metabolism. | Mol Cell Oncol | 2020 |
| 33037181 | Mitochondrial ClpP serine protease-biological function and emerging target for cancer therapy. | Cell Death Dis | 2020 |
| 32609586 | Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia. | JCO Oncol Pract | 2020 |
| 32944624 | Targeting neurolysin in acute myeloid leukemia. | Mol Cell Oncol | 2020 |
| 32996267 | COVID-19: a pandemic experience that illuminates potential reforms to health research. | EMBO Mol Med | 2020 |
| 32624581 | Targeting nuclear import and export in hematological malignancies. | Leukemia | 2020 |
| 32761807 | The role of mitochondrial proteases in leukemic cells and leukemic stem cells. | Stem Cells Transl Med | 2020 |
| 32749766 | Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. | Mol Oncol | 2020 |
| 32416059 | Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal. | Cell Stem Cell | 2020 |
| 32269163 | The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. | Sci Transl Med | 2020 |
| 32299104 | Mitochondrial carrier homolog 2 is necessary for AML survival. | Blood | 2020 |
| 32484839 | Correction: The Natural Pesticide Dihydrorotenone Induces Human Plasma Cell Apoptosis by Triggering Endoplasmic Reticulum Stress and Activating p38 Signaling Pathway. | PLoS One | 2020 |
| 32395867 | Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. | Br J Haematol | 2020 |
| 30535882 | Pain in patients with newly diagnosed or relapsed acute leukemia. | Support Care Cancer | 2019 |